Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Myotonic dystrophy (DM) of type 1 and 2 (DM1 and DM2) are inherited autosomal dominant diseases caused by dynamic and unstable expanded microsatellite sequences (CTG and CCTG, respectively) in the non-coding regions of the genes DMPK and ZNF9, respectively. These mutations result in the intranuclear accumulation of mutated transcripts and the mis-splicing of numerous transcripts. This so-called RNA gain of toxic function is the main feature of an emerging group of pathologies known as RNAopathies. Interestingly, in addition to these RNA inclusions, called foci, the presence of neurofibrillary tangles (NFT) in patient brains also distinguishes DM as a tauopathy. Tauopathies are a group of nearly 30 neurodegenerative diseases that are characterized by intraneuronal protein aggregates of the microtubule-associated protein Tau (MAPT) in patient brains. Furthermore, a number of neurodegenerative diseases involve the dysregulation of splicing regulating factors and have been characterized as spliceopathies. Thus, myotonic dystrophies are pathologies resulting from the interplay among RNAopathy, spliceopathy, and tauopathy. This review will describe how these processes contribute to neurodegeneration. We will first focus on the tauopathy associated with DM1, including clinical symptoms, brain histology, and molecular mechanisms. We will also discuss the features of DM1 that are shared by other tauopathies and, consequently, might participate in the development of a tauopathy. Moreover, we will discuss the determinants common to both RNAopathies and spliceopathies that could interfere with tau-related neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936 · cited 1×
“[244] [245] [246] [247] [248] [249]).”
A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD
Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.010 · Cited by 4,409
Strong association of de novo copy number mutations with autism
Sebat, J., Lakshmi, B., Malhotra, D., Troge, J., Lese-Martin, C., Walsh, T., Yamrom, B., Yoon, S., Krasnitz, A., Kendall, J., et al. (2007) · Science · doi:10.1126/science.1138659 · Cited by 2,795 · cited 1×
“The hnRNP A1 polymorphism is a genetic factor for some FTLD [285], and mutated RBFox1 has been associated with mental retardation, epilepsy, and autism spectrum disorders [286] [287] [288] [289].”
BackgroundTDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis
Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., Ackerley, S., Durnall, J. C., Williams, K. L., Buratti, E., et al. (2008) · Science · doi:10.1126/science.1154584 · Cited by 2,630 · cited 1×
“Other neurological pathologies associated with the dysfunction of RNA-binding factors include ALS and FTD, which is induced by mutations in the TDP-43 and FUS genes [268] [269] [270].”
BackgroundTransmission and spreading of tauopathy in transgenic mouse brain
Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis
Kabashi, E., Valdmanis, P. N., Dion, P., Spiegelman, D., McConkey, B. J., Velde, C. V., Bouchard, J.-P., Lacomblez, L., Pochigaeva, K., Salachas, F., et al. (2008) · Nature Genetics · doi:10.1038/ng.132 · Cited by 1,544
Propagation of Tau Pathology in a Model of Early Alzheimer's Disease
de Calignon, A., Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D. H., Kopeikina, K. J., Pitstick, R., Sahara, N., Ashe, K. H., Carlson, G. A., et al. (2012) · Neuron · doi:10.1016/j.neuron.2011.11.033 · Cited by 1,427
Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43
Polymenidou, M., Lagier-Tourenne, C., Hutt, K. R., Huelga, S. C., Moran, J., Liang, T. Y., Ling, S.-C., Sun, E., Wancewicz, E., Mazur, C., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2779 · Cited by 1,335
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 4×
“, and Mieda-Sato, A. (2012). TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes.”
BackgroundInfluentialGenome-wide Analysis of Genetic Loci Associated With Alzheimer Disease
Seshadri, S. (2010) · JAMA · doi:10.1001/jama.2010.574 · Cited by 1,219
Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease
Giannakopoulos, P., Herrmann, F. R., Bussière, T., Bouras, C., Kövari, E., Perl, D. P., Morrison, J. H., Gold, G., & Hof, P. R. (2003) · Neurology · doi:10.1212/01.wnl.0000063311.58879.01 · Cited by 1,118 · cited 5×
“et al. (2011). A comprehensive genetic association study of Alzheimer disease”
BackgroundInfluentialDifferential Regulation of Dynein and Kinesin Motor Proteins by Tau
Dixit, R., Ross, J. L., Goldman, Y. E., & Holzbaur, E. L. F. (2008) · Science · doi:10.1126/science.1152993 · Cited by 1,012 · cited 5×
“The perturbations of kinesin and dynein-dynactin migration are both dependent on the Tau isoform; the shortest Tau isoform (0N3R) is a more potent inhibitor than the longest isoform (2N4R) (Dixit et al., 2008).”
BackgroundInfluentialTDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease
Amador‐Ortiz, C., Lin, W., Ahmed, Z., Personett, D., Davies, P., Duara, R., Graff‐Radford, N. R., Hutton, M. L., & Dickson, D. W. (2007) · Annals of Neurology · doi:10.1002/ana.21154 · Cited by 916 · cited 1×
“SRP20, TDP-43, hnRNP-A/B, and CELF2 have been associated with AD [290], [291, 292] [293], [206], and SFPQ has been associated with AD and PiD [294].”
BackgroundDe Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607483200 · Cited by 882
A Muscleblind Knockout Model for Myotonic Dystrophy
Kanadia, R. N., Johnstone, K. A., Mankodi, A., Lungu, C., Thornton, C. A., Esson, D., Timmers, A. M., Hauswirth, W. W., & Swanson, M. S. (2003) · Science · doi:10.1126/science.1088583 · Cited by 743
Berg, L., McKeel, D. W., Miller, J. P., Storandt, M., Rubin, E. H., Morris, J. C., Baty, J., Coats, M., Norton, J., Goate, A. M., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.3.326 · Cited by 657 · cited 2×
“The density and topographic progression of NFTs have been correlated with disease severity and cognitive decline in AD patients (Duyckaerts et al., 1997; Berg et al., 1998; Giannakopoulos et al., 2003; Bennett et al., 2004).”
BackgroundStructural Polymorphism of 441-Residue Tau at Single Residue Resolution
Mukrasch, M. D., Bibow, S., Korukottu, J., Jeganathan, S., Biernat, J., Griesinger, C., Mandelkow, E., & Zweckstetter, M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000034 · Cited by 652
Ball, M. J. (1977) · Acta Neuropathologica · doi:10.1007/bf00692056 · Cited by 639
Bennett, D. A., Schneider, J. A., Wilson, R. S., Bienias, J. L., & Arnold, S. E. (2004) · Archives of Neurology · doi:10.1001/archneur.61.3.378 · Cited by 526 · cited 2×
“The density and topographic progression of NFTs have been correlated with disease severity and cognitive decline in AD patients (Duyckaerts et al., 1997; Berg et al., 1998; Giannakopoulos et al., 2003; Bennett et al., 2004).”
BackgroundFailure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy
Lin, X., Miller, J. W., Mankodi, A., Kanadia, R. N., Yuan, Y., Moxley, R. T., Swanson, M. S., & Thornton, C. A. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl132 · Cited by 510
A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart
Kalsotra, A., Xiao, X., Ward, A. J., Castle, J. C., Johnson, J. M., Burge, C. B., & Cooper, T. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809045105 · Cited by 508 · cited 1×
“In these tissues, CELF1 and MBNL1 are antagonistic regulators of many splicing events altered in DM1, and these events are oppositely regulated during development: CELF1 expression decreases whereas MBNL1 increases during heart development in mice [113].”
BackgroundAlzheimer brain-derived tau oligomers propagate pathology from endogenous tau
Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Guerrero-Munoz, M. J., Kiritoshi, T., Neugebauer, V., Jackson, G. R., & Kayed, R. (2012) · Scientific Reports · doi:10.1038/srep00700 · Cited by 502
Multiple-motor based transport and its regulation by Tau
Vershinin, M., Carter, B. C., Razafsky, D. S., King, S. J., & Gross, S. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607919104 · Cited by 457 · cited 2×
“First, Tau 3R has a more significant effect than Tau 4R on both kinesin and dynein binding and progression along stabilized microtubules [155, 157] [158], while Tau 4R but not Tau 3R enhances the velocity of kinesin [159].”
BackgroundIncreased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology
GERAD consortium, Chapuis, J., Hansmannel, F., Gistelinck, M., Mounier, A., Van Cauwenberghe, C., Kolen, K. V., Geller, F., Sottejeau, Y., Harold, D., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.1 · Cited by 407
Self-citationGoode, B., & Feinstein, S. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.5.769 · Cited by 399
Uryu, K., Nakashima-Yasuda, H., Forman, M. S., Kwong, L. K., Clark, C. M., Grossman, M., Miller, B. L., Kretzschmar, H. A., Lee, V. M.-Y., Trojanowski, J. Q., et al. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31817713b5 · Cited by 382
Trinczek, B., Ebneth, A., Mandelkow, E.-M., & Mandelkow, E. (1999) · Journal of Cell Science · doi:10.1242/jcs.112.14.2355 · Cited by 344
U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer’s disease
Bai, B., Hales, C. M., Chen, P.-C., Gozal, Y., Dammer, E. B., Fritz, J. J., Wang, X., Xia, Q., Duong, D. M., Street, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310249110 · Cited by 335 · cited 1×
“The accumulation of both U1SnRNP and U1-70K, elements essential to the splicing mechanism, has recently been associated with AD and unspliced RNA accumulation [301].”
BackgroundAndreadis, A. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.08.010 · Cited by 311
Biochemistry of Tau in Alzheimer’s disease and related neurological disorders
Sergeant, N., Bretteville, A., Hamdane, M., Caillet-Boudin, M.-L., Grognet, P., Bombois, S., Blum, D., Delacourte, A., Pasquier, F., Vanmechelen, E., et al. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.207 · Cited by 300
Self-citationJeganathan, S., von Bergen, M., Mandelkow, E.-M., & Mandelkow, E. (2008) · Biochemistry · doi:10.1021/bi800783d · Cited by 286 · cited 4×
“Tau protein structure Tau is a ‘‘natively unfolded’’ protein [129] [130], but short sequences (maximum of 10 residues) transiently adopt secondary structures, facilitating transient functions such as protein-protein interactions [131].”
BackgroundInfluentialBosco, D., Fava, A., Plastino, M., Montalcini, T., & Pujia, A. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01318.x · Cited by 283
Widespread binding of FUS along nascent RNA regulates alternative splicing in the brain
Rogelj, B., Easton, L. E., Bogu, G. K., Stanton, L. W., Rot, G., Curk, T., Zupan, B., Sugimoto, Y., Modic, M., Haberman, N., et al. (2012) · Scientific Reports · doi:10.1038/srep00603 · Cited by 278 · cited 1×
“RNA splicing regulator [281], particularly for Tau and RNA-binding protein splicing [282] [283], has only recently been described.”
BackgroundSingle-molecule investigation of the interference between kinesin, tau and MAP2c
Seitz, A., Kojima, H., Oiwa, K., Mandelkow, E.-M., Song, Y.-H., & Mandelkow, E. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf503 · Cited by 257 · cited 1×
“…Tau affects organelle transport by reducing the attachment frequency of motors to microtubules (Sato-Harada et al., 1996; Trinczek et al., 1999; Seitz et al., 2002; Mandelkow et al., 2004) or differentially regulating kinesin- and dynein-based transport (Dixit et al., 2008; Vershinin et al.,…”
BackgroundTrabzuni, D., Wray, S., Vandrovcova, J., Ramasamy, A., Walker, R., Smith, C., Luk, C., Gibbs, J. R., Dillman, A., Hernandez, D. G., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds238 · Cited by 252
Fallini, C., Bassell, G. J., & Rossoll, W. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds205 · Cited by 247
NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation
Amadoro, G., Ciotti, M. T., Costanzi, M., Cestari, V., Calissano, P., & Canu, N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511065103 · Cited by 243 · cited 1×
“As a feedback loop, NMDAR stimulation causes calpain activation, followed by Tau protein proteolysis, resulting in highly toxic N-terminal peptides, such as the 17-kDa peptide [233].”
BackgroundMARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons
Mandelkow, E.-M., Thies, E., Trinczek, B., Biernat, J., & Mandelkow, E. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200401085 · Cited by 236
Are tau aggregates toxic or protective in tauopathies?
Cowan, C. M., & Mudher, A. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00114 · Cited by 215
Shahpasand, K., Uemura, I., Saito, T., Asano, T., Hata, K., Shibata, K., Toyoshima, Y., Hasegawa, M., & Hisanaga, S.-I. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5927-11.2012 · Cited by 206 · cited 1×
“Indeed, the space between microtubules was recently shown to be a potential determinant in mitochondrial transport (Shahpasand et al., 2012).”
BackgroundDementia From Alzheimer Disease and Mixed Pathologies in the Oldest Old
James, B. D. (2012) · JAMA · doi:10.1001/jama.2012.3556 · Cited by 199 · cited 2×
“In DM1 brains, no amyloid/senile plaques have been described (Figure 1), and α-synuclein inclusions (LBs) have scarcely been observed (Kiuchi et al., 1991; James et al., 2012) (Maurage and Sergeant, unpublished results).”
BackgroundCytogenetic and molecular characterization of A2BP1/FOX1 as a candidate gene for autism
Martin, C. L., Duvall, J. A., Ilkin, Y., Simon, J. S., Arreaza, M. G., Wilkes, K., Alvarez‐Retuerto, A., Whichello, A., Powell, C. M., Rao, K., et al. (2007) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30530 · Cited by 198 · cited 1×
“The hnRNP A1 polymorphism is a genetic factor for some FTLD [285], and mutated RBFox1 has been associated with mental retardation, epilepsy, and autism spectrum disorders [286] [287] [288] [289].”
BackgroundMicrotubule bundling by tau proteins in vivo: analysis of functional domains
Kanai, Y., Chen, J., & Hirokawa, N. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05489.x · Cited by 194
Ghoshal, N. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.8014 · Cited by 192
Rademakers, R., Melquist, S., Cruts, M., Theuns, J., Del-Favero, J., Poorkaj, P., Baker, M., Sleegers, K., Crook, R., De Pooter, T., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi361 · Cited by 164 · cited 9×
“Myotonic dystrophy (DM) of type I (DM1), which is also referred to as dystrophia myotonica or Steinert’s disease, is the most common form of adult-onset muscular dystrophy and affects at Abbreviations: 3′ UTR, 3′ untranslated region; Aβ, amyloid beta; AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; APP, a…”
BackgroundInfluentialEffect of Intranasal Insulin on Cognitive Function: A Systematic Review
Shemesh, E., Rudich, A., Harman-Boehm, I., & Cukierman-Yaffe, T. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1802 · Cited by 162
Modeling the Relation Between Neurofibrillary Tangles and Intellectual Status
Duyckaerts, C. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)80306-5 · Cited by 150
Bhalla, K., Phillips, H. A., Crawford, J., McKenzie, O. L. D., Mulley, J. C., Eyre, H., Gardner, A. E., Kremmidiotis, G., & Callen, D. F. (2004) · Journal of Human Genetics · doi:10.1007/s10038-004-0145-4 · Cited by 146 · cited 1×
“The hnRNP A1 polymorphism is a genetic factor for some FTLD [285], and mutated RBFox1 has been associated with mental retardation, epilepsy, and autism spectrum disorders [286] [287] [288] [289].”
BackgroundEkström, A., Hakenäs‐Plate, L., Samuelsson, L., Tulinius, M., & Wentz, E. (2008) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30698 · Cited by 136 · cited 2×
“Furthermore, approximately half of these young patients also have autism spectrum disorders, the frequency of which is related to the number of CTG repeat (Ekstrom et al., 2008).”
BackgroundDifferential effect of three‐repeat and four‐repeat tau on mitochondrial axonal transport
Stoothoff, W., Jones, P. B., Spires‐Jones, T. L., Joyner, D., Chhabra, E., Bercury, K., Fan, Z., Xie, H., Bacskai, B., Edd, J., et al. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06316.x · Cited by 135
Tau isoform composition influences rate and extent of filament formation
Zhong, Q., Congdon, E. E., Nagaraja, H. N., & Kuret, J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.364067 · Cited by 122
A New Member of the Amphiphysin Family Connecting Endocytosis and Signal Transduction Pathways
Leprince, C., Romero, F., Cussac, D., Vayssiere, B., Berger, R., Tavitian, A., & Camonis, J. H. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.24.15101 · Cited by 89
McVicker, D. P., Chrin, L. R., & Berger, C. L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.292987 · Cited by 85 · cited 2×
“First, Tau 3R has a more significant effect than Tau 4R on both kinesin and dynein binding and progression along stabilized microtubules (Vershinin et al., 2007, 2008; Stoothoff et al., 2009), while Tau 4R but not Tau 3R enhances the velocity of kinesin (McVicker et al., 2011).”
BackgroundTuning microtubule-based transport through filamentous MAPs: the problem of dynein
Vershinin, M., Xu, J., Razafsky, D. S., King, S. J., & Gross, S. P. (2008) · Traffic · doi:10.1111/j.1600-0854.2008.00741.x · Cited by 76
Quantitative analysis of tau isoform transcripts in sporadic tauopathies
Connell, J. W., Rodriguez-Martin, T., Gibb, G. M., Kahn, N. M., Grierson, A. J., Hanger, D. P., Revesz, T., Lantos, P. L., Anderton, B. H., & Gallo, J.-M. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2005.02.014 · Cited by 70
Single molecule profiling of tau gene expression in Alzheimer’s disease
Conrad, C., Zhu, J., Conrad, C., Schoenfeld, D., Fang, Z., Ingelsson, M., Stamm, S., Church, G., & Hyman, B. T. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04857.x · Cited by 68
Pseudohyperphosphorylation Has Differential Effects on Polymerization and Function of Tau Isoforms
Combs, B., Voss, K., & Gamblin, T. C. (2011) · Biochemistry · doi:10.1021/bi2010569 · Cited by 41 · cited 2×
“…cellular model, Tau pseudo-phosphorylation at sites common to the different Tau isoforms inhibits the aggregation of all 3R isoforms but has little effect on the aggregation of 2N4R (2+3+10+ isoform) and 1N4R (2+10+ isoform), and enhances the aggregation of 0N4R (10+ isoform) (Combs et al., 2011).”
Background(2016) · doi:10.1210/er · Cited by 37
Cited by
microRNA dysregulation in neurodegenerative diseases: A systematic review
Juźwik, C. A., S. Drake, S., Zhang, Y., Paradis-Isler, N., Sylvester, A., Amar-Zifkin, A., Douglas, C., Morquette, B., Moore, C. S., & Fournier, A. E. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101664 · Cited by 426
Metadata
- Authors
- Caillet-Boudin, M.-L., Fernandez-Gomez, F.-J., Tran, H., Dhaenens, C.-M., Buee, L., & Sergeant, N.
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2014
- Volume
- 6
- Pages
- 57-57
- ISSN
- 1662-5099 (ISSN-L)
- OpenAlex
- W2102099323
- Cited by
- 99
- References
- 61
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.